Literature DB >> 2166150

Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases.

J Lowe1, H McDermott, M Landon, R J Mayer, K D Wilkinson.   

Abstract

The recent discovery that brain PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase suggests that the role of this protein should be studied in relation to ubiquitinated cellular inclusions characteristic of several chronic human degenerative diseases. Formalin-fixed, paraffin-processed sections known to contain ubiquitin-protein conjugate immunoreactivity in cortical Lewy bodies, neurofibrillary tangles, Rosenthal fibres, Pick bodies, spinal inclusions in motor neurone disease, and Mallory's hyaline in alcoholic liver disease were immunostained to localize PGP 9.5. The majority of cortical Lewy bodies in diffuse Lewy body disease showed immunoreactivity for PGP 9.5. In Alzheimer's disease, only a minority of loosely arranged globose-type neurofibrillary tangles were immunostained together with a minority of neurites surrounding senile plaques. In cerebellar astrocytomas, the periphery of the majority of Rosenthal fibers was immunostained in addition to strong diffuse cytoplasmic immunostaining in some astrocytes lacking apparent Rosenthal fibers. In Pick's disease, there was no immunostaining of inclusions but there was intense immunostaining of swollen Pick cells. No spinal inclusions in motor neurone disease were stained; however, anterior horn neurones appear to show increased levels of PGP 9.5 compared with those from control cases. No immunostaining of hepatic Mallory's hyaline was demonstrable, which accords with suggestions that PGP 9.5 is a tissue-specific ubiquitin C-terminal hydrolase isoenzyme. The differential detection of a ubiquitin C-terminal hydrolase in different forms of ubiquitinated inclusion body in the nervous system may form the basis of a method for assessment of the staging of inclusion body biogenesis and give insight into the dynamics of inclusion body formation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2166150     DOI: 10.1002/path.1711610210

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  78 in total

1.  Neuropathology in mice expressing human alpha-synuclein.

Authors:  H van der Putten; K H Wiederhold; A Probst; S Barbieri; C Mistl; S Danner; S Kauffmann; K Hofele; W P Spooren; M A Ruegg; S Lin; P Caroni; B Sommer; M Tolnay; G Bilbe
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

Review 2.  The genetic basis of Parkinson's disease.

Authors:  T Foltynie; S Sawcer; C Brayne; R A Barker
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-10       Impact factor: 10.154

Review 3.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

Review 4.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

5.  Rosenthal fibers contain ubiquitinated alpha B-crystallin.

Authors:  J E Goldman; E Corbin
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

6.  Intraneuronal dopamine-quinone synthesis: a review.

Authors:  D Sulzer; L Zecca
Journal:  Neurotox Res       Date:  2000-02       Impact factor: 3.911

7.  Ubiquitin carboxyl-terminal hydrolase L1 is required for maintaining the structure and function of the neuromuscular junction.

Authors:  Fujun Chen; Yoshie Sugiura; Kalisa Galina Myers; Yun Liu; Weichun Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

Review 8.  Parkinsonism in motor neuron disease: case report and literature review.

Authors:  T L Williams; P J Shaw; J Lowe; D Bates; P G Ince
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

9.  Gene expression profiles of mouse striatum in control and maneb + paraquat-induced Parkinson's disease phenotype: validation of differentially expressed energy metabolizing transcripts.

Authors:  Suman Patel; Kavita Singh; Seema Singh; Mahendra Pratap Singh
Journal:  Mol Biotechnol       Date:  2008-04-02       Impact factor: 2.695

10.  Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin.

Authors:  Helen C Ardley; Gina B Scott; Stephen A Rose; Nancy G S Tan; Alexander F Markham; Philip A Robinson
Journal:  Mol Biol Cell       Date:  2003-08-22       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.